Description
Composition- Linagliptin 5 mg + Dapagliflozin 10 mg
Mode of Action- Provides dual oral diabetes control through incretin pathway enhancement and increased urinary glucose excretion.
USPs- Dual mechanism antidiabetic therapy; low hypoglycemia risk; useful where metformin-free combination is preferred.
Prescribing Specialties- Diabetologist, General Physician
